Leveraging Novel Modalities for Oncology Therapies

DATE

October 26, 2022

TIME

8:00 a.m. PDT, 11:00 a.m. EDT, 16:00 BST, 17:00 CEST

Duration: 60 Minutes

Overview

Over the last two decades, traditional small molecules and antibody drugs have provided tremendous benefits to cancer patients. Due to the complexity of the disease, incomplete response and drug resistance ultimately emerge. New modalities beyond traditional small molecules and antibodies can provide unprecedented opportunities for drugs previously deemed “undruggable” targets. As an example, KRASG12C covalent inhibitors have shown promise for the treatment of Non-small cell lung cancer with KRASG12C mutations. Other KRAS mutants which cannot be inhibited by covalent inhibitors remain “undruggable”. In this webinar, we will discuss the opportunity of new modalities like oligonucleotides and TCR-engineered T cell therapy for treating KRAS mutant cancers, as well as various modality toolboxes to support drug discovery programs.

Key Learning Objectives:

Review and highlight the use of various drug modalities in oncology
Dive into specific examples of different modalities for a particular target and learn key takeaways

Who Should Attend:

Scientists (biologist, oncologist, chemist, etc.)
Program leaders and strategists
Project managers
Medical doctors
Individuals interested in understanding how a new modalities could expand therapies

Brought to you by:

Speakers

Werngard Czechtizky
Executive Director Head Medicinal Chemistry, Chair of AZ Global Chemistry Leadership,
Astrazeneca

Luping Lin
Director Biology,
WuXi AppTec

Jiafeng Rui
Associate Director, Biology,
WuXi AppTec

Melissa O'Meara
Forensic Science Consultant,
C&EN Media Group

Registration

Forwarded this event? Clear the form

Email Address*

Salutation

First Name*

Last Name*

Company*

Job Title*

Address 1

City*

State*

Zip / Post Code

Country*

Business Phone

What modality are you most interested in?*

Yes, we would like to learn more about the uses and challenges of RNA-based therapies for treating c

Yes, we are interested in developing T cell therapies, including TCR-T, as treatments against solid

I would like to receive more information on products and services from the American Chemical Society

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.

View On Demand Webinars